CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	[1]
Current assets:
Cash and cash equivalents	$ 413,147	$ 278,096
Short-term marketable securities	3,999	72,749
Related party receivables from collaborative arrangements	82,402	79,427
Prepaid expenses and other current assets	645	962
Total current assets	500,193	431,234
Property and equipment, net	37	33
Equity investments	128,613	0
Capitalized fees paid to a related party, net	132,164	139,076
Deferred tax assets, net	118,348	154,171
Other assets	264	312
Total assets	879,619	724,826
Current liabilities:
Accounts payable	195	10
Accrued personnel-related expenses	291	647
Accrued interest payable	4,152	4,152
Other accrued liabilities	776	562
Total current liabilities	5,414	5,371
Long-term debt, net of discount and issuance costs	381,230	377,120
Other long-term liabilities	163	219
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding	0	0
Common stock: $0.01 par value, 200,000 shares authorized, 101,392 and 101,288 issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	1,015	1,013
Additional paid-in capital	1,260,017	1,258,859
Accumulated other comprehensive income (loss)	(2)	27
Accumulated deficit	(804,123)	(946,404)
Total Innoviva stockholders' equity	456,907	313,495
Noncontrolling interest	35,905	28,621
Total stockholders' equity	492,812	342,116
Total liabilities and stockholders' equity	$ 879,619	$ 724,826

[1] Consolidated balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements.